At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 117 enrolled
Drug / intervention
LEO 90100drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
In Brief
A Phase 2 clinical trial evaluating LEO 90100 for Psoriasis Vulgaris. Completed, enrolled 117 participants across 9 sites in 4 countries.
Detailed Summary
An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis Vulgaris
CountriesNetherlands, Poland, Romania, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 2015
Enrollment StartMar 2016
Primary CompletionMar 2018
TodayJul 2026
First PostedMar 13, 2015
Enrollment StartMar 1, 2016
Primary CompletionMar 28, 2018
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 11.3 years ago
Interventions
LEO 90100drug